JP2012236837A5 - - Google Patents

Download PDF

Info

Publication number
JP2012236837A5
JP2012236837A5 JP2012158751A JP2012158751A JP2012236837A5 JP 2012236837 A5 JP2012236837 A5 JP 2012236837A5 JP 2012158751 A JP2012158751 A JP 2012158751A JP 2012158751 A JP2012158751 A JP 2012158751A JP 2012236837 A5 JP2012236837 A5 JP 2012236837A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
suspension
polymer
phthalate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012158751A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012236837A (ja
Filing date
Publication date
Priority claimed from AUPQ4854A external-priority patent/AUPQ485499A0/en
Priority claimed from AUPQ7450A external-priority patent/AUPQ745000A0/en
Application filed filed Critical
Publication of JP2012236837A publication Critical patent/JP2012236837A/ja
Publication of JP2012236837A5 publication Critical patent/JP2012236837A5/ja
Pending legal-status Critical Current

Links

JP2012158751A 1999-12-23 2012-07-17 不良溶解性の薬物に対する改良された医薬組成物 Pending JP2012236837A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPQ4854A AUPQ485499A0 (en) 1999-12-23 1999-12-23 Improved pharmaceutical compositions for poorly soluble drugs
AUPQ4854 1999-12-23
AUPQ7450A AUPQ745000A0 (en) 2000-05-12 2000-05-12 Improved pharmaceutical compositions for poorly soluble drugs
AUPQ7450 2000-05-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001548087A Division JP5159012B2 (ja) 1999-12-23 2000-12-22 不良溶解性の薬物に対する改良された医薬組成物

Publications (2)

Publication Number Publication Date
JP2012236837A JP2012236837A (ja) 2012-12-06
JP2012236837A5 true JP2012236837A5 (https=) 2013-05-30

Family

ID=25646230

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001548087A Expired - Fee Related JP5159012B2 (ja) 1999-12-23 2000-12-22 不良溶解性の薬物に対する改良された医薬組成物
JP2012158751A Pending JP2012236837A (ja) 1999-12-23 2012-07-17 不良溶解性の薬物に対する改良された医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001548087A Expired - Fee Related JP5159012B2 (ja) 1999-12-23 2000-12-22 不良溶解性の薬物に対する改良された医薬組成物

Country Status (8)

Country Link
US (3) US20030086976A1 (https=)
EP (2) EP2415462A1 (https=)
JP (2) JP5159012B2 (https=)
AU (2) AU782469B2 (https=)
CA (1) CA2396380C (https=)
ES (1) ES2398643T3 (https=)
PT (1) PT1239831E (https=)
WO (1) WO2001047492A1 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs
GB0012448D0 (en) 2000-05-24 2000-07-12 Astrazeneca Ab New process
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
GB0104752D0 (en) * 2001-02-27 2001-04-18 Astrazeneca Ab Pharmaceutical compositions
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
DE60313359T2 (de) * 2002-12-17 2008-01-03 Abbott Gmbh & Co. Kg Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7507823B2 (en) 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
JP2007308480A (ja) * 2006-04-20 2007-11-29 Shin Etsu Chem Co Ltd 腸溶性固体分散体を含んでなる固形製剤
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
WO2008002568A2 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
ZA200905094B (en) * 2006-12-22 2010-09-29 Yuhan Corp Revaprazan-containing solid dispersion and process for the preparation thereof
WO2008110534A1 (en) * 2007-03-13 2008-09-18 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
CN104983701A (zh) * 2008-04-15 2015-10-21 默沙东公司 优选含有泊沙康唑和hpmcas的固体分散体形式的口服药物组合物
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
ES2695099T3 (es) * 2011-11-23 2019-01-02 Array Biopharma Inc Formulaciones farmacéuticas
US9650851B2 (en) 2012-06-18 2017-05-16 Schlumberger Technology Corporation Autonomous untethered well object
BR112014031706A8 (pt) * 2012-06-21 2021-10-19 Mayne Pharma Int Pty Ltd Composições farmacêuticas orais, e composição farmacêutica oral compreendendo itraconazol
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
EP2837391B1 (en) 2013-08-12 2017-05-10 Shin-Etsu Chemical Co., Ltd. Hypromellose acetate succinate for use as hot-melt extrusion carrier, hot-melt extrusion composition, and method for producing hot-melt extrudate
CN104644557B (zh) * 2013-11-22 2017-10-31 上海宣泰医药科技有限公司 卟啉铁固体分散体及其制备方法
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
ES3063790T3 (en) 2015-06-09 2026-04-20 Lonza Sales Ag Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
JP2020506905A (ja) * 2017-01-20 2020-03-05 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． （ｒ）−ｎ−（（４−メトキシ−６−メチル−２−オキソ−１，２−ジヒドロピリジン−３−イル）メチル）−２−メチル−１−（１−（１−（２，２，２−トリフルオロエチル）ピペリジン−４−イル）エチル）−１ｈ−インドール−３−カルボキサミド固体分散液
US11390613B2 (en) 2017-08-20 2022-07-19 University Of Connecticut Azole analogues and methods of use thereof
AU2019308326B2 (en) 2018-07-20 2025-07-31 Lipocine Inc. Liver disease
WO2020159562A1 (en) 2019-01-29 2020-08-06 Slayback Pharma Llc Pharmaceutical compositions of posaconazole
US11318107B2 (en) 2019-02-22 2022-05-03 Avior, Inc. Pharmaceutical active-containing film delivery device for oral transmucosal administration
WO2021030174A1 (en) 2019-08-09 2021-02-18 University Of Connecticut Truncated itraconazole analogues and methods of use thereof
PH12022550492A1 (en) * 2019-08-28 2022-12-19 Shenzhen Chipscreen Biosciences Co Ltd Chidamide pharmaceutical composition, preparation method therefor and application thereof
CN115768779A (zh) 2020-05-07 2023-03-07 上海偕怡医药科技有限公司 伊曲康唑前药及其用途
EP4452232A1 (en) * 2021-12-22 2024-10-30 Palau Pharma, S.L.U. Multiparticulate albaconazole composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02167219A (ja) * 1988-12-20 1990-06-27 Fujisawa Pharmaceut Co Ltd 固体分散体の製造方法
JP3110794B2 (ja) 1991-06-05 2000-11-20 ユーシービージャパン株式会社 １，４−ジヒドロピリジン誘導体を含有する製剤
US5340591A (en) * 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6254889B1 (en) 1995-07-26 2001-07-03 Kyowa Hakko Kogyo Co., Ltd. Solid dispersion dosage form of amorphous xanthine derivative and enteric-coating polymer
ATE255883T1 (de) * 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
DE69730241T2 (de) * 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
ATE364374T1 (de) * 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
CA2317106C (en) * 1997-12-31 2004-11-23 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19843904A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
JP2002534371A (ja) * 1999-01-06 2002-10-15 コリア リサーチ インスティテュート オブ ケミカル テクノロジー 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP2415462A1 (en) * 1999-12-23 2012-02-08 Mayne Pharma International Pty Ltd. Improved pharmaceutical compositions for poorly soluble drugs

Similar Documents

Publication Publication Date Title
JP2012236837A5 (https=)
RU2016147198A (ru) Лекарственные формы для пероральной доставки адсорбентов в кишечник
JP2017500332A (ja) 経口医薬組成物
RU2014127142A (ru) Фармацевтическая композиция с улучшенной биодоступностью для высокоплавкого гидрофобного соединения
JP2017536398A5 (https=)
EA033370B1 (ru) Составы рифаксимина и их применение
JP2014523445A5 (https=)
JP2009502969A5 (https=)
RU2011150228A (ru) Системы пленочного покрытия для препаратов с немедленным высвобождением, создающие усиленный барьер от влаги, и субстраты с таким покрытием
RU2014152031A (ru) Составы твердых дозированных лекарственных форм антагониста орексинового рецептора
CN101808622A (zh) 含有埃索美拉唑的药物组合物
JP2009537611A5 (ja) リポ酸のペレット
JP2013103899A (ja) 難溶性薬物の新規な固体分散体
CN104922086A (zh) 一种质子泵抑制剂肠溶片的制备方法
CN103919735B (zh) 一种盐酸坦索罗辛缓释微丸及其制备方法
JP2019509345A5 (https=)
WO2011098194A3 (en) Pharmaceutical mini-tablets for sustained release of flecainide acetate
CN104146978B (zh) 一种双硫仑肠溶片剂及其制备方法
HRP20200780T1 (hr) Formulacija za kontrolirano otpuštanje hidrokortizona
Obara et al. Properties and applications of hypromellose acetate succinate (HPMCAS) for solubility enhancement using melt extrusion
JP6441811B2 (ja) 複合体形成用組成物、そこから形成された複合体、及びそれを含む経口摂取用組成物
CN104188935B (zh) 一种兰索拉唑肠溶片及其制备方法
RU2015141792A (ru) Сухие фармацевтические композиции, включающие наночастицы активного агента, связанные с частицами носителя
CN104800184B (zh) 琥珀酸呋罗曲坦缓释剂片
Cheng et al. Aqueous polymer dispersion coating used for osmotic pump tablets: membrane property investigation and IVIVC evaluation